Paying users zone. Data is covered by .

  • Get to Biogen Inc. for $15.99, or

  • get to whole website for at least 3 months from $49.99.

 

$15.99


Ratios (Summary)

Biogen Inc., long-term (investment) activity ratios

 
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Net fixed asset turnover
Total asset turnover
Equity turnover

Source: Based on data from Biogen Inc. Annual Reports

Ratio Description The company
Net fixed asset turnover An activity ratio calculated as total revenue divided by net fixed assets. Biogen Inc.'s net fixed asset turnover deteriorated from 2015 to 2016 and from 2016 to 2017.
Total asset turnover An activity ratio calculated as total revenue divided by total assets. Biogen Inc.'s total asset turnover deteriorated from 2015 to 2016 but then slightly improved from 2016 to 2017.
Equity turnover An activity ratio calculated as total revenue divided by shareholders' equity. Biogen Inc.'s equity turnover deteriorated from 2015 to 2016 but then slightly improved from 2016 to 2017.

Top


Net Fixed Asset Turnover

Biogen Inc., net fixed asset turnover calculation, comparison to benchmarks

 
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Selected Financial Data (USD $ in thousands)
Revenues
Property, plant and equipment, net
Ratio
Net fixed asset turnover1
Benchmarks
Net Fixed Asset Turnover, Competitors
Abbott Laboratories
AbbVie Inc.
Allergan PLC
Amgen Inc.
Bristol-Myers Squibb Co.
Celgene Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Net Fixed Asset Turnover, Sector
Pharmaceuticals & Biotechnology
Net Fixed Asset Turnover, Industry
Health Care

Source: Based on data from Biogen Inc. Annual Reports

2017 Calculations

1 Net fixed asset turnover = Revenues ÷ Property, plant and equipment, net
= ÷ =

Ratio Description The company
Net fixed asset turnover An activity ratio calculated as total revenue divided by net fixed assets. Biogen Inc.'s net fixed asset turnover deteriorated from 2015 to 2016 and from 2016 to 2017.

Top


Total Asset Turnover

Biogen Inc., total asset turnover calculation, comparison to benchmarks

 
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Selected Financial Data (USD $ in thousands)
Revenues
Total assets
Ratio
Total asset turnover1
Benchmarks
Total Asset Turnover, Competitors
Abbott Laboratories
AbbVie Inc.
Allergan PLC
Amgen Inc.
Bristol-Myers Squibb Co.
Celgene Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Total Asset Turnover, Sector
Pharmaceuticals & Biotechnology
Total Asset Turnover, Industry
Health Care

Source: Based on data from Biogen Inc. Annual Reports

2017 Calculations

1 Total asset turnover = Revenues ÷ Total assets
= ÷ =

Ratio Description The company
Total asset turnover An activity ratio calculated as total revenue divided by total assets. Biogen Inc.'s total asset turnover deteriorated from 2015 to 2016 but then slightly improved from 2016 to 2017.

Top


Equity Turnover

Biogen Inc., equity turnover calculation, comparison to benchmarks

 
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Selected Financial Data (USD $ in thousands)
Revenues
Total Biogen Inc. shareholders' equity
Ratio
Equity turnover1
Benchmarks
Equity Turnover, Competitors
Abbott Laboratories
AbbVie Inc.
Allergan PLC
Amgen Inc.
Bristol-Myers Squibb Co.
Celgene Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Equity Turnover, Sector
Pharmaceuticals & Biotechnology
Equity Turnover, Industry
Health Care

Source: Based on data from Biogen Inc. Annual Reports

2017 Calculations

1 Equity turnover = Revenues ÷ Total Biogen Inc. shareholders' equity
= ÷ =

Ratio Description The company
Equity turnover An activity ratio calculated as total revenue divided by shareholders' equity. Biogen Inc.'s equity turnover deteriorated from 2015 to 2016 but then slightly improved from 2016 to 2017.

Top